Peptide Comparison
Retatrutide vs Survodutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two glucagon-receptor agonists in the same regimen: High risk per peptide research literature. Overlapping glucagon-receptor activation drives hepatic glucose output, hepatic lipid mobilization, and resting heart rate; stacking compounds metabolic and cardiovascular load with no clinical precedent.
Data-derived verdict
Retatrutide and Survodutide share the glp-1 / glucagon-agonist classes and carry roughly equivalent evidence (Phase 3 / Phase 3). On the catalogued data layer Survodutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Survodutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: gi side effects. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Retatrutide | Survodutide | |
|---|---|---|
| Class | GIP/GLP-1/glucagon triple agonist | GLP-1/glucagon dual agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects | Dual GLP-1/glucagon receptor activation |
| Route | SC injection | SC injection |
| Half-life | ~6 days | Long-acting weekly |
| Dosage (research) | 2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk) | 0.6-4.8 mg SC weekly |
| Evidence tier | Phase 3 | Phase 3 |
| Research depth | 217 indexed | 126 indexed |
| Availability | Investigational | Investigational |
| Reported risks | GI side effects; Phase 3 ongoing; long-term safety unknown | GI side effects; injection reactions |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Retatrutide or Survodutide?
Retatrutide and Survodutide share the glp-1 / glucagon-agonist classes and carry roughly equivalent evidence (Phase 3 / Phase 3). On the catalogued data layer Survodutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Survodutide's evidence base is currently denser.
What is the difference between Retatrutide and Survodutide?
Retatrutide is classed as GIP/GLP-1/glucagon triple agonist; Survodutide is classed as GLP-1/glucagon dual agonist. Reported mechanism: Retatrutide, Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects; Survodutide, Dual GLP-1/glucagon receptor activation. Reported half-life: Retatrutide, ~6 days; Survodutide, Long-acting weekly. Routes in published studies: Retatrutide, SC injection; Survodutide, SC injection.
Which has stronger evidence, Retatrutide or Survodutide?
Retatrutide and Survodutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Retatrutide is graded Phase 3, with 29 cited sources on its reference page and 217 indexed studies. Survodutide is graded Phase 3, with 33 cited sources on its reference page and 126 indexed studies.
Which is more accessible, Retatrutide or Survodutide?
Neither Retatrutide nor Survodutide is an FDA-approved drug. Catalog status: Retatrutide, Investigational; Survodutide, Investigational.
Are Retatrutide and Survodutide ever combined?
Retatrutide and Survodutide appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two glucagon-receptor agonists in the same regimen, high risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…